Search results
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Zacks via Yahoo Finance· 1 month agoPacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201,...
Pacira (PCRX) Loses -17.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks via Yahoo Finance· 1 year agoPacira (PCRX) has become technically an oversold stock now, which implies exhaustion of the heavy...
Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?
Zacks via Yahoo Finance· 1 year agoPacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over...
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Zacks via Yahoo Finance· 2 months agoPacira BioSciences, Inc. PCRX reported fourth-quarter 2023 adjusted earnings of 89 cents per share,...
Unveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive Guide
GuruFocus.com via Yahoo Finance· 7 months agoWith a day's loss of -2.26%, a 3-month loss of -17.45%, and a Loss Per Share of 0.16, Pacira...
Here’s What Makes Pacira BioSciences (PCRX) a Great Buy
Insider Monkey via Yahoo Finance· 2 years agoCarillon Tower Advisers, an investment management firm, published its “Carillon Scout Small Cap...
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Zacks via Yahoo Finance· 2 years agoPacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings...
Pacira BioSciences Inc (PCRX) Reports Q3 2023 Financial Results
GuruFocus.com via Yahoo Finance· 6 months agoPacira BioSciences Inc (NASDAQ:PCRX) reported total revenues of $163.9 million in Q3 2023, a slight...
Pacira (PCRX) Lags Q3 Earnings Estimates
Zacks via Yahoo Finance· 1 year agoPacira (PCRX) delivered earnings and revenue surprises of -12.33% and 0.10%, respectively, for the quarter ended September 2022. Do the numbers hold...
